Meeting
2022 ASCO Annual Meeting
Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding, in patients with advanced solid tumors.
Authors
James Robert Vasselli
Aulos Bioscience, Larkspur, CA
James Robert Vasselli , Sophia Frentzas , Andrew James Weickhardt , Paul L. de Souza , Jenny Tang , Tim Wyant , Inbar Amit , Yanay Ofran , Aron Knickerbocker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
CT-2021-CTN-03938-1
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2671)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2671
Abstract #
TPS2671
Poster Bd #
324b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
In vitro and in vivo characterization of MDNA11: A long-acting “beta-only” IL-2 superkine in syngeneic mice tumor models and nonhuman primates.
First Author: Moutih Rafei
Poster
2019 ASCO Annual Meeting
Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.
First Author: Ulka N. Vaishampayan
Poster
2022 ASCO Annual Meeting
A first-in-human, multicenter, phase 1/2, open-label study of XTX202, a masked and tumor-selective recombinant human interleukin-2 (IL-2) protein, in patients with advanced solid tumors.
First Author: Meredith McKean
Poster
2022 ASCO Annual Meeting
ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumors.
First Author: Sarina Anne Piha-Paul